Literature DB >> 1544941

Human erythrocyte protein 4.2, a high copy number membrane protein, is N-myristylated.

M A Risinger1, E M Dotimas, C M Cohen.   

Abstract

Band 4.2 is a major protein of the erythrocyte membrane which has been immunologically detected in a variety of cell types and is apparently essential for normal erythrocyte membrane function. Since band 4.2 has unusual solubility and membrane binding properties and has an N-terminal glycine following the initiating methionine, we explored the possibility that band 4.2 is myristylated. When Sf9 cells infected with a recombinant band 4.2 Baculovirus were incubated with [3H]myristic acid, label became incorporated into recombinant band 4.2 protein and resisted extraction with hydroxylamine. Consistent with N-terminal myristylation, the incorporation of label was dependent upon protein synthesis. The fatty acid covalently bound to recombinant band 4.2 was definitively identified as myristic acid by recovering the fatty acid after hydrolysis of band 4.2 and examining its migration relative to standards in thin layer chromatography. It was determined that native erythrocyte band 4.2 is an N-myristylated protein by reverse phase high performance liquid chromatography detection of an azlactone derivative of N-myristylglycine after mild acid hydrolysis and azlactone derivatization of the purified protein. Study of myristylation of band 4.2, an abundant normal cellular protein, and its role in membrane binding may produce insights relevant to other myristylated cellular proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544941

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Mapping of a spectrin-binding domain of human erythrocyte membrane protein 4.2.

Authors:  Debabrata Mandal; Prasun K Moitra; Joyoti Basu
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

2.  Mapping of a palmitoylatable band 3-binding domain of human erythrocyte membrane protein 4.2.

Authors:  R Bhattacharyya; A K Das; P K Moitra; B Pal; I Mandal; J Basu
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

3.  Associations of protein 4.2 with band 3 and ankyrin.

Authors:  Yang Su; Yu Ding; Ming Jiang; Weihua Jiang; Xiaojian Hu; Zhihong Zhang
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

4.  Molecular basis of bovine red-cell protein 4.2 polymorphism in Japanese black cattle.

Authors:  M Matsumoto; M Inaba; K Ono
Journal:  Biochem J       Date:  1998-05-15       Impact factor: 3.857

5.  Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies.

Authors:  Hong Jiang; Xiaoyu Zhang; Xiao Chen; Pornpun Aramsangtienchai; Zhen Tong; Hening Lin
Journal:  Chem Rev       Date:  2018-01-02       Impact factor: 60.622

6.  Architecture of the human erythrocyte ankyrin-1 complex.

Authors:  Francesca Vallese; Kookjoo Kim; Laura Y Yen; Jake D Johnston; Alex J Noble; Tito Calì; Oliver Biggs Clarke
Journal:  Nat Struct Mol Biol       Date:  2022-07-14       Impact factor: 18.361

7.  Protein 4.2 binds to the carboxyl-terminal EF-hands of erythroid alpha-spectrin in a calcium- and calmodulin-dependent manner.

Authors:  Catherine Korsgren; Luanne L Peters; Samuel E Lux
Journal:  J Biol Chem       Date:  2009-12-11       Impact factor: 5.157

Review 8.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Molecular cloning of mouse erythrocyte protein 4.2: a membrane protein with strong homology with the transglutaminase supergene family.

Authors:  A C Rybicki; R S Schwartz; J J Qiu; J G Gilman
Journal:  Mamm Genome       Date:  1994-07       Impact factor: 2.957

Review 10.  Refined views of multi-protein complexes in the erythrocyte membrane.

Authors:  T J Mankelow; T J Satchwell; N M Burton
Journal:  Blood Cells Mol Dis       Date:  2012-03-31       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.